{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:01:34Z","timestamp":1791003694386,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Sodium\u2010glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycemic agents that improve glycemic control by increasing glycosuria. Additional benefits beyond glucose lowering include significant improvements in seated clinic blood pressure (BP), partly attributed to their diuretic\u2010like actions. Less known are the effects of this class on 24\u2010hour ambulatory BP, which is a better predictor of cardiovascular risk than seated clinic BP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              We performed a meta\u2010analysis of randomized, double\u2010blind, placebo\u2010controlled trials to investigate the effects of SGLT2 inhibitors on 24\u2010hour ambulatory BP. We searched all studies published before August 17, 2016, which reported 24\u2010hour ambulatory BP data. Mean differences in 24\u2010hour BP, daytime BP, and nighttime BP were calculated by a random\u2010effects model. SGLT2 inhibitors significantly reduce 24\u2010hour ambulatory systolic and diastolic BP by \u22123.76\u00a0mm\u00a0Hg (95% CI, \u22124.23 to \u22122.34; I\n              <jats:sup>2<\/jats:sup>\n              =0.99) and \u22121.83\u00a0mm\u00a0Hg (95% CI, \u22122.35 to \u22121.31; I\n              <jats:sup>2<\/jats:sup>\n              =0.76), respectively. Significant reductions in daytime and nighttime systolic and diastolic BP were also found. No association between baseline BP or change in body weight were observed.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">This meta\u2010analysis shows that the reduction in 24\u2010hour ambulatory BP observed with SGLT2 inhibitors is a class effect. The diurnal effect of SGLT2 inhibitors on 24\u2010hour ambulatory BP may contribute to their favorable effects on cardiovascular outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.117.005686","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T20:10:26Z","timestamp":1495138226000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":168,"title":["Effects of Sodium\u2010Glucose Cotransporter 2 Inhibitors on 24\u2010Hour Ambulatory Blood Pressure: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1161","volume":"6","author":[{"given":"William L.","family":"Baker","sequence":"first","affiliation":[{"name":"University of Connecticut School of Pharmacy","place":["Storrs"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo F.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Pharmacy","place":["Richmond"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Chapman University School of Pharmacy","place":["Irvine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Bucheit","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Pharmacy","place":["Richmond"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Parod","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Pharmacy","place":["Richmond"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Brown","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University","place":["Richmond"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University","place":["Richmond"]},{"name":"Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University","place":["Richmond"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Pharmacy","place":["Richmond"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo RA","year":"2016","unstructured":"DeFronzo RA, Norton L, Abdul\u2010Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2016;13:11\u201326.","journal-title":"Nat Rev Nephrol"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co\u2010transporter 2 inhibitor","volume":"53","author":"Scheen AJ","year":"2014","unstructured":"Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co\u2010transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213\u2013225.","journal-title":"Clin Pharmacokinet"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedi JC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u20132128.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_5_2","unstructured":"U.S. Food and Drug Administration . FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm531517.htm. Accessed January 11 2017."},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium\u2010glucose co\u2010transporter 2 inhibitors on blood pressure: a systematic review and meta\u2010analysis","volume":"8","author":"Baker WL","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium\u2010glucose co\u2010transporter 2 inhibitors on blood pressure: a systematic review and meta\u2010analysis. J Am Soc Hypertens. 2014;8:262\u2013275.","journal-title":"J Am Soc Hypertens"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink HJL","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u2013772.","journal-title":"Circulation"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000170138.56903.7a","article-title":"Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study","volume":"46","author":"Dolan E","year":"2005","unstructured":"Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156\u2013161.","journal-title":"Hypertension"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/HYPERTENSIONAHA.111.00289","article-title":"Masked hypertension in diabetes mellitus: treatment implications for clinical practice","volume":"61","author":"Franklin SS","year":"2013","unstructured":"Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, Asayama K, Bjorklund\u2010Bodegard K, Ohkubo T, Jeppesen J, Torp\u2010Pedersen C, Dolan E, Kuznetsova T, Stolarz\u2010Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka\u2010Jaszcz K, Filipovsky J, Imai Y, Wang J, Ibsen H, O'Brien E, Staessen JA; International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes Investigators . Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension. 2013;61:964\u2013971.","journal-title":"Hypertension"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1161\/CIRCULATIONAHA.116.023404","article-title":"Clinic blood pressure underestimates ambulatory blood pressure in an untreated employer\u2010based US population: results from the Masked Hypertension Study","volume":"134","author":"Schwartz JE","year":"2016","unstructured":"Schwartz JE, Burg MM, Shimbo D, Broderick JE, Stone AA, Ishikawa J, Sloan R, Yurgel T, Grossman S, Pickering TG. Clinic blood pressure underestimates ambulatory blood pressure in an untreated employer\u2010based US population: results from the Masked Hypertension Study. Circulation. 2016;134:1794\u20131807.","journal-title":"Circulation"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/2046\u20104053\u20104\u20101"},{"key":"e_1_3_1_12_2","unstructured":"Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)\u2010EHC063\u2010EF. Rockville MD: Agency for Healthcare Research and Quality; 2014. Chapters Available at: www.effectivehealthcare.ahrq.gov. Accessed April 12 2017."},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u201014\u201025"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta\u2010analyses","volume":"327","author":"Higgins JPT","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta\u2010analyses. BMJ. 2003;327:557\u2013560.","journal-title":"BMJ"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta\u2010analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta\u2010analysis detected by a simple, graphical test. BMJ. 1997;315:629\u2013634.","journal-title":"BMJ"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24\u2010hour ambulatory blood pressure after 6\u2010week Treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend RR","year":"2016","unstructured":"Townsend RR, Machin I, Ren J, Trujillo A, Kawaguchi M, Vijapurkar U, Damaraju CV, Pfeifer M. Reductions in mean 24\u2010hour ambulatory blood pressure after 6\u2010week Treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension. J Clin Hypertens (Greenwich). 2016;18:43\u201352.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose\u2010regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers\u2010Heerspink HJ","year":"2013","unstructured":"Lambers\u2010Heerspink HJ, De Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose\u2010regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853\u2013862.","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin\u2010angiotensin system blockade","volume":"25","author":"Weber MA","year":"2016","unstructured":"Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin\u2010angiotensin system blockade. Blood Press. 2016;25:93\u2013103.","journal-title":"Blood Press"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double\u2010blind, placebo\u2010controlled, phase 3 study","volume":"4","author":"Weber MA","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double\u2010blind, placebo\u2010controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211\u2013220.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen I","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420\u2013428.","journal-title":"Diabetes Care"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.12486","article-title":"Blood pressure lowering effect of the sodium glucose co\u2010transporter\u20102 inhibitor, ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension","volume":"17","author":"Amin NB","year":"2015","unstructured":"Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM. Blood pressure lowering effect of the sodium glucose co\u2010transporter\u20102 inhibitor, ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805\u2013808.","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA\u2010SU): 52\u00a0week results from a randomised, double\u2010blind, phase 3 non\u2010inferiority trial","volume":"382","author":"Cefalu WT","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon K\u2010H, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA\u2010SU): 52\u00a0week results from a randomised, double\u2010blind, phase 3 non\u2010inferiority trial. Lancet. 2013;382:941\u2013950.","journal-title":"Lancet"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","article-title":"Sodium\u2013glucose cotransporter\u20102 inhibition and the potential for renal protection in diabetic nephropathy","volume":"24","author":"\u0160krti\u0107 M","year":"2015","unstructured":"\u0160krti\u0107 M, Cherney DZI. Sodium\u2013glucose cotransporter\u20102 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015;24:96\u2013103.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1464-5491.2005.01554.x","article-title":"Does metformin decrease blood pressure in patients with type 2 diabetes intensively treated with insulin?","volume":"22","author":"Wulffel\u00e9 MG","year":"2005","unstructured":"Wulffel\u00e9 MG, Kooy A, Lehert P, Betst D, Donker AJM, Stehouwer CD. Does metformin decrease blood pressure in patients with type 2 diabetes intensively treated with insulin? Diabet Med. 2005;22:907\u2013913.","journal-title":"Diabet Med"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase\u20104 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry GC","year":"2008","unstructured":"Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase\u20104 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592\u2013598.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475\u20102840\u20109\u20106"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin JA","year":"2015","unstructured":"Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38:132\u2013139.","journal-title":"Diabetes Care"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","article-title":"Effects of the once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus","volume":"64","author":"Ferdinand KC","year":"2014","unstructured":"Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731\u2013737.","journal-title":"Hypertension"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475\u20102840\u20107\u201010"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1152\/ajprenal.00149.2007","article-title":"Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes","volume":"293","author":"Tiwari S","year":"2007","unstructured":"Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007;293:974\u2013984.","journal-title":"Am J Physiol Renal Physiol"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/01.HYP.32.2.243","article-title":"Insulin resistance and the effect of insulin on blood pressure in essential hypertension","volume":"32","author":"Heise T","year":"1998","unstructured":"Heise T, Magnusson K, Heinemann L, Sawicki PT. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension. 1998;32:243\u2013248.","journal-title":"Hypertension"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure","volume":"108","author":"Nesto RW","year":"2003","unstructured":"Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation. 2003;108:2941\u20132948.","journal-title":"Circulation"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Matthewus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u2013334.","journal-title":"N Engl J Med"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010016\u20100403\u20108"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ajh.2008.4","article-title":"Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with\/without type 2 diabetes","volume":"21","author":"Eguchi K","year":"2008","unstructured":"Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Schwartz JE, Shimada K, Kario K. Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with\/without type 2 diabetes. Am J Hypertens. 2008;21:443\u2013450.","journal-title":"Am J Hypertens"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/HYPERTENSIONAHA.107.100727","article-title":"Daytime and nighttime blood pressure as predictors of death and cause\u2010specific cardiovascular events in hypertension","volume":"51","author":"Fagard RH","year":"2008","unstructured":"Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause\u2010specific cardiovascular events in hypertension. Hypertension. 2008;51:55\u201361.","journal-title":"Hypertension"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.116.024764","article-title":"Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Greater Power Comes Great Responsibility","volume":"134","author":"Cherney DZ","year":"2016","unstructured":"Cherney DZ, Udell JA. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Greater Power Comes Great Responsibility. Circulation. 2016;134:1915\u20131917.","journal-title":"Circulation"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.117.005686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T23:32:14Z","timestamp":1760484734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.005686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1161\/JAHA.117.005686"],"URL":"https:\/\/doi.org\/10.1161\/jaha.117.005686","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2017-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e005686"}}